Study to Evaluate HER2-neu Expression in Different Histopathological Grades of Prostatic Carcinoma in a Tertiary Care Centre, Bareilly

Study to Evaluate HER2-neu Expression in Different Histopathological Grades of Prostatic Carcinoma in a Tertiary Care Centre, Bareilly

Introduction: Prostate cancer is the second most common neoplasm among men around the world. Two routinely used immunocytochemical markers for prostatic epithelium are Prostatic Acid Phosphatase (PAP) and Prostatic Specific Antigen (PSA). Various other markers like Prostate-Specific Membrane An...

Full description

Bibliographic Details
Main Authors:	SURBHI BANSAL, HEMA PANT, TANU AGRAWAL, PIYUSH KUMAR, PRADEEP MEHDIRATTA
Format:	Article
Language:	English
Published:	JCDR Research and Publications Private Limited 2020-12-01
Series:	Journal of Clinical and Diagnostic Research
Subjects:	prostatic adenocarcinoma prostatic specific antigen trastuzumab
Online Access:	https://jcdr.net/articles/PDF/14358/45082_CE(Ra1)_P(AK)_PF1_(AD_OM)_PN(SL).pdf

Similar Items

Correlation of serum prostate-specific antigen with gleason's score/grade group in prostate cancers and their histopathological findings: A 4-year retrospective study at a tertiary care center
by: Ritu Sharma, et al.
Published: (2023-01-01)

Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
by: Albouzidi Abderrahmane, et al.
Published: (2011-09-01)

Expression of Her2-Neu in Primary Gastric and Gastroesophageal Adenocarcinoma: An Experience from a Tertiary Center in South India
by: Aditi Damle, et al.

Correlation between prostate-specific antigen and histopathological difference of prostate carcinoma
by: Živković Slađana
Published: (2004-01-01)

Free PSA and prostate volume on the diagnosis of prostate carcinoma
by: Antonio Carlos Pereira Martins, et al.
Published: (2003-01-01)

Association of Connexin 32 with Prostate Volume and PSA Level in Prostatic Adenocarcinoma and Adenomyomatous Hyperplasia
by: Havva Erdem, et al.
Published: (2020-06-01)

The Effectiveness of Trastuzumab Combined with Sequential Chemotherapy for Metastatic Gastric Carcinoma with Overexpression of HER2
by: Omar Saavedra Santa Gadea, et al.
Published: (2017-07-01)

A Study on TRUS-Guided Prostatic Biopsy and its Correlation with Serum PSA, Gleason Score and Grade-Grouping in a Tertiary Care Centre of Eastern India
by: GOPINATH BARUI, et al.
Published: (2019-03-01)

Investigation of the Cut-off Value for Prostate-Specific Antigen in Patients referring to Shahid Beheshti Hospital of Babol
by: H Shafi, et al.
Published: (2015-08-01)

Metastatic Prostatic Adenocarcinoma in an Inguinal Hernia Sac in a Patient with Undetectable Serum Prostate Specific Antigen Level
by: Shiu-Dong Chung, et al.
Published: (2007-05-01)

PATTERN OF PROSTATE SPECIFIC ANTIGEN AND GLEASON SCORE IN RELATION TO IMUNOHISTOCHEMISTRY FEATURES IN PROSTATE ADENOCARCINOMA PATIENTS IN DR. HASAN SADIKIN GENERAL HOSPITAL
by: Azela Glady, et al.
Published: (2016-03-01)

CORRELATION BETWEEN BLOOD SERUM PSA LEVEL AND MMP-2 IN PROSTATE ADENOCARCINOMA
by: Anny Setijo Rahaju, et al.
Published: (2016-09-01)

Association between gleason score, psa level, PSAD and prostate volume, in a series of patients with prostate adenocarcinoma
by: Benedetti-Padrón Inés, et al.
Published: (2012-06-01)

Effect of Chronic Urinary Retention over Serum Prostate-Specific Antigen and Its Role in Histopathological Diagnosis
by: Sahil Verma, et al.
Published: (2022-01-01)

Effect of Finasteride on PSA and Histopathological Results in Patients Undergoing Prostate Biopsy
by: Saman Farshid, et al.
Published: (2022-12-01)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
by: Salkeni MA, et al.
Published: (2021-09-01)

Five-Year Profiles of Prostate Cancer Patients in A Tertiary Hospital in Indonesia
by: Ferry Safriadi, et al.
Published: (2021-06-01)

Specificity and sensitivity of preoperative total serum prostate specific antigen in diagnosis most common histopathological change of prostate
by: Mijović Milica, et al.
Published: (2017-01-01)

Impact on prostate cancer clinical presentation after non-screening policies at a tertiary-care medical center- a retrospective study
by: Tarek Ajami, et al.
Published: (2021-02-01)

Cutaneous metastases of prostatic adenocarcinoma
by: Shashikant CU Patne, et al.
Published: (2015-01-01)

Targeting HER2 in Gastroesophageal Adenocarcinoma: Molecular Features and Updates in Clinical Practice
by: Maria Bonomi, et al.
Published: (2024-03-01)

Xanthogranulomatous Prostatitis, a Rare Prostatic Entity
by: Alejandro Noyola, et al.
Published: (2017-01-01)

Incidental prostate cancer: a 23-year review of a tertiary care hospital
by: Abdul khalique, et al.
Published: (2023-07-01)

HER2 expression, gene amplification and chromosome 17 copy number in primary pancreatic adenocarcinoma, matastatic lymph node and metastasis
by: S. Boccardo, et al.
Published: (2011-01-01)

Validity of Prostate Health Index and Percentage of [-2] Pro-Prostate-Specific Antigen as Novel Biomarkers in the Diagnosis of Prostate Cancer: Omani Tertiary Hospitals Experience
by: Safana S. Al Saidi, et al.
Published: (2017-07-01)

Defining Oligometastatic Disease in the New Era of PSMA-PET Imaging for Primary Staging of Prostate Cancer
by: Samuel J. Galgano, et al.
Published: (2022-07-01)

Recommendations of Test of Prostate-specific Antigen along with Histopathological Examination for the Prostate Lesions
by: Pallavi Gedam, et al.
Published: (2019-10-01)

DIAGNOSIS OF PROSTATIC NEOPLASM LATER TO ANTIBIOTIC TREATMENT IN PATIENTS WITH PROSTATE-SPECIFIC ANTIGEN BETWEEN 4 AND 10 ng/ml (IN SPANISH)
by: Infantes-Burgos Ronald Javier, et al.
Published: (2014-01-01)

Elevated prostate volume index and prostatic chronic inflammation reduce the number of positive cores at first prostate biopsy set: results in 945 consecutive patients
by: Antonio B. Porcaro, et al.

Prostate-specific antigen velocity in diagnosis and prognosis of prostate cancer - a systematic review
by: Arslaan Javaeed, et al.
Published: (2020-05-01)

CUT-OFF POINT OF PSA AND PSA DENSITY IN PROSTATE CANCER SUSPECTED PATIENTS
by: Daniel Simanjuntak, et al.
Published: (2016-03-01)

Contemporary Review of Multimodality Imaging of the Prostate Gland
by: Carli E. Calderone, et al.
Published: (2023-05-01)

Nonspecific granulomatous prostatitis with prostatic adenocarcinoma
by: Murugan Paari, et al.
Published: (2010-01-01)

Histomorphologic Correlation of PSA Levels in Prostatic Pathology
by: Deepak Panasseril Jayapradeep, et al.
Published: (2017-10-01)

The Value of Prostate-Specific Antigen-Related Indexes and Imaging Screening in the Diagnosis of Prostate Cancer
by: Bai X, et al.
Published: (2020-08-01)

Free prostate-specific antigen outperforms total prostate-specific antigen as a predictor of prostate volume in patients without prostate cancer
by: Sinan Avci, et al.
Published: (2020-04-01)

Prostatic adenocarcinoma with a peculiar morphology – a rare case of pseudohyperplastic variant with inverted polarity
by: Daniel Abensur Athanazio, et al.
Published: (2022-02-01)

Histopathological characteristics of a novel knock-in mouse prostate cancer model
by: G. Wu, et al.
Published: (2006-06-01)

Prostate-specific antigen and prostate-specific antigen density cutoff points among Indonesian population suspected for prostate cancer
by: Ahmad Anies Shahab, et al.
Published: (2013-03-01)

Immunohistochemical Study of Tumor Cells Proliferative Activity at Different Graduations of Prostate Cancer
by: G. Y. Kudryavtsev, et al.
Published: (2019-12-01)